down arrow

D. Western Therapeutics Institute, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: JP3548740004
  • TKS: 4576
JPY
70.00
-1 (-1.41%)

Sep 25

TKS

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
RaQualia Pharma, Inc.
Pharmarise Holdings Corp.
Wakamoto Pharmaceutical Co., Ltd.
Solasia Pharma KK
Renascience, Inc.
D. Western Therapeutics Institute, Inc.
SymBio Pharmaceuticals Ltd.
Nippon Chemiphar Co., Ltd.
CanBas Co., Ltd.
BrightPath Biotherapeutics Co., Ltd.
Delta-Fly Pharma, Inc.

Why is D. Western Therapeutics Institute, Inc. ?

1
The company has declared Negative results for the last 17 consecutive quarters
  • INTEREST(HY) At JPY 6.5 MM has Grown at 63.15%
  • NET SALES(Q) At JPY 18.03 MM has Fallen at -76.43%
  • INVENTORY TURNOVER RATIO(HY) Lowest at 0.42 times
2
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of -34.26%, its profits have risen by 38.4%
3
Underperformed the market in the last 1 year
  • Even though the market (Japan Nikkei 225) has generated returns of 43.58% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -34.26% returns
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is D. Western Therapeutics Institute, Inc. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
D. Western Therapeutics Institute, Inc.
-55.7%
-0.42
50.27%
Japan Nikkei 225
43.58%
1.48
29.43%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
-3.76%
EBIT Growth (5y)
-184.13%
EBIT to Interest (avg)
-153.54
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.63
Sales to Capital Employed (avg)
0.24
Tax Ratio
0.24%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.06
EV to EBIT
-4.77
EV to EBITDA
-5.06
EV to Capital Employed
8.35
EV to Sales
10.06
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-175.03%
ROE (Latest)
-49.67%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
Mildly Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

6What is working for the Company
NET PROFIT(HY)

Higher at JPY -323.11 MM

ROCE(HY)

Highest at -55.66%

RAW MATERIAL COST(Y)

Fallen by -20.23% (YoY

-21What is not working for the Company
INTEREST(HY)

At JPY 6.5 MM has Grown at 63.15%

NET SALES(Q)

At JPY 18.03 MM has Fallen at -76.43%

INVENTORY TURNOVER RATIO(HY)

Lowest at 0.42 times

DEBTORS TURNOVER RATIO(HY)

Lowest at 2.8 times

Here's what is working for D. Western Therapeutics Institute, Inc.

Net Profit
Higher at JPY -323.11 MM
than preceding 12 month period ended Jun 2026
MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (JPY MM)

Raw Material Cost
Fallen by -20.23% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Depreciation
At JPY 1.85 MM has Grown at 61.06%
period on period (QoQ)
MOJO Watch
The expenditure on assets done by the company has gone into productive use which should positively reflect in the future sales

Depreciation (JPY MM)

Here's what is not working for D. Western Therapeutics Institute, Inc.

Interest
At JPY 6.5 MM has Grown at 63.15%
over previous Semi-Annual period
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (JPY MM)

Net Sales
At JPY 18.03 MM has Fallen at -76.43%
over average net sales of the previous four periods of JPY 76.49 MM
MOJO Watch
Near term sales trend is extremely negative

Net Sales (JPY MM)

Inventory Turnover Ratio
Lowest at 0.42 times
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Debtors Turnover Ratio
Lowest at 2.8 times
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Footer loading